Imbalanced kynurenine pathway in schizophrenia

Area of Science:

• Neuroscience
• Biochemistry
• Psychiatry

Background:

• Kynurenic acid (KYNA) is implicated in schizophrenia pathophysiology.
• Elevated KYNA in schizophrenia may stem from a kynurenine pathway shift favoring KYNA over quinolinic acid (QUIN).

Purpose of the Study:

• To investigate cerebrospinal fluid (CSF) levels of QUIN in schizophrenia patients and controls.
• To correlate CSF QUIN levels with KYNA and other kynurenine metabolites.
• To examine the QUIN/KYNA ratio in schizophrenia.

Main Methods:

• CSF samples analyzed from stable, olanzapine-treated schizophrenia outpatients (n=22) and healthy controls (n=26).
• Liquid chromatography-mass spectrometry used for QUIN, KYNA, and kynurenine quantification.
• Statistical analysis to compare groups and assess correlations.

Main Results:

• No significant difference in CSF QUIN levels between schizophrenia patients and controls.
• CSF QUIN positively correlated with CSF kynurenine and KYNA in patients, but not controls.
• The CSF QUIN/KYNA ratio was significantly lower in patients compared to controls (P=0.027).

Conclusions:

• Findings support an over-activated and imbalanced kynurenine pathway in schizophrenia.
• The imbalance favors KYNA production over QUIN.
• This supports the role of kynurenine pathway dysregulation in schizophrenia's pathophysiology.